Evidence map›Paper›PMID 37768414›Full record

SynthesisAnnals of surgical oncology2024

Malignant Solid Pseudopapillary Neoplasm of the Pancreas: An Orthogonal Analysis.

Andrew M Fleming, Leah E Hendrick, Danny Yakoub, Hafeez Abdelhafeez, Jeremiah L Deneve, Max R Langham, Evan S Glazer, Andrew M Davidoff, Nipun B Merchant, Paxton V Dickson and 1 more

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Andrew M FlemingDepartment of Surgery, The University of Tennessee Health Science Center, Memphis, TN, USA. aflemin8@uthsc.edu.ORCID http://orcid.org/0000-0001-5421-9014
Leah E HendrickDepartment of Surgery, The University of Tennessee Health Science Center, Memphis, TN, USA.
Danny YakoubDepartment of Surgery, Augusta University Medical Center, Augusta, GA, USA.
Hafeez AbdelhafeezDepartment of Surgery, The University of Tennessee Health Science Center, Memphis, TN, USA.
Jeremiah L DeneveDepartment of Surgery, University of North Carolina, Chapel Hill, NC, USA.
Max R LanghamDepartment of Surgery, The University of Tennessee Health Science Center, Memphis, TN, USA.
Evan S GlazerDepartment of Surgery, The University of Tennessee Health Science Center, Memphis, TN, USA.
Andrew M DavidoffDepartment of Surgery, The University of Tennessee Health Science Center, Memphis, TN, USA.
Nipun B MerchantDepartment of Surgery, University of Miami Health System, Miami, FL, USA.
Paxton V Dickson *Department of Surgery, The University of Tennessee Health Science Center, Memphis, TN, USA.
Andrew J Murphy *Department of Surgery, The University of Tennessee Health Science Center, Memphis, TN, USA.
St. Jude Children's Research Hospital · USUniversity of Tennessee Health Science Center · USAugusta University Health · USUniversity of Miami Health System · USUniversity of North Carolina at Chapel Hill · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic solid pseudopapillary neoplasms (SPN) are generally indolent; however, some patients present with "malignant" SPN. An orthogonal analysis of multiple datasets was performed to investigate the utility of complete surgical resection (CSR) for malignant SPN.

methodsA systematic review was performed for cases of malignant SPN, defined as T4, N1, and/or M1. Malignant SPN was analyzed within the National Cancer Database (NCDB) and compared with T1-3N0M0 SPN. Predictors of malignant SPN were assessed, and treatments were analyzed by using survival analysis.

resultsThe systematic review yielded 164 cases of malignant SPN. Of 31 children, only one died due to malignant SPN. Among adults, CSR was associated with improved disease-specific survival (DSS) (P = 0.0002). Chemotherapy did not improve malignant SPN DSS, whether resected (P = 0.8485) or not (P = 0.2219). Of 692 adults with SPN within the NCDB, 93 (13.4%) had malignant SPN. Pancreatic head location (odds ratio [OR] 2.174; 95% confidence interval [CI] 1.136-4.166; P = 0.0186) and tumor size (OR 1.154; 95% CI 1.079-1.235; P < 0.0001) associated with the malignant phenotype. Malignant SPN predicted decreased overall survival (OS) compared with T1-3N0M0 disease (P < 0.0001). Resected malignant SPN demonstrated improved OS (P < 0.0001), including resected stage IV malignant SPN (P = 0.0003). Chemotherapy did not improve OS for malignant SPN, whether resected (P = 0.8633) or not (P = 0.5734). Within a multivariable model, resection was associated with decreased hazard of death (hazard ratio 0.090; 95% CI 0.030-0.261; P < 0.0001).

conclusionsApproximately 13% of patients with SPN present with a malignant phenotype. Pediatric cases may be less aggressive. Resection may improve survival for malignant SPN, which does not appear chemosensitive.

Indexed as

Carcinoma, PapillaryPancreatic NeoplasmsAdultChildHumansPancreasPancreatectomyPancreaticoduodenectomy

Identifiers

PMID37768414
OpenAlexW4387114967

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.